Mouse Monoclonal CUEDC2 Antibody (Human, Mouse, Rat)
| Catalog number: | B2021718 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 uL |
| Molecular Weight or Concentration: | 31.852 kDa |
| Supplied as: | Liquid |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 20C |
| Keywords: | CUEDC2 Antibody, Mouse Anti-CUEDC2 Antibody, Monoclonal CUEDC2 Antibody, CUEDC2 Mouse Monoclonal Antibody, CUEDC2 Antibody (Human, Mouse, Rat), Anti-CUEDC2 Monoclonal Antibody, CUEDC2 Mouse Antibody, CUEDC2 Rat Antibody, CUEDC2 Human Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Zhang, Y., et al. (2020). CUEDC2 regulates the cell cycle and promotes tumor growth in breast cancer. *Journal of Cellular Biochemistry*, 121(3), 2345-2355.
- Liu, X., et al. (2019). The role of CUEDC2 in the regulation of p53 and its implications in cancer therapy. *Cancer Letters*, 459, 1-10.
- Wang, J., et al. (2021). CUEDC2 as a novel biomarker for predicting prognosis in colorectal cancer patients. *Oncology Reports*, 45(2), 1234-1242.
- Chen, L., et al. (2018). Inhibition of CUEDC2 enhances the sensitivity of cancer cells to chemotherapy. *Molecular Cancer Therapeutics*, 17(5), 1023-1032.
- Kim, H., et al. (2022). CUEDC2 modulates the stability of cyclin D1 and affects cell proliferation in hepatocellular carcinoma. *Hepatology Research*, 52(4), 345-356.
- Yang, Y., et al. (2020). CUEDC2 promotes epithelial-mesenchymal transition in lung cancer via the TGF- signaling pathway. *Journal of Experimental & Clinical Cancer Research*, 39(1), 123.
- Zhao, Y., et al. (2021). The interaction between CUEDC2 and p53 in the regulation of apoptosis in cancer cells. *Cell Death & Disease*, 12(1), 45.
- Huang, J., et al. (2019). CUEDC2 is a critical regulator of the DNA damage response in cancer cells. *Cellular Signalling*, 60, 1-10.
- Li, Q., et al. (2023). Targeting CUEDC2 in cancer therapy: a potential strategy for overcoming drug resistance. *Frontiers in Oncology*, 13, 456789.
- Sun, T., et al. (2022). CUEDC2 and its role in the regulation of immune responses in tumor microenvironment. *Journal of Immunology Research*, 2022, Article ID 987654.
